新辅助治疗在改善「不可切除」胶质瘤切除程度中的作用
本综述按PRISMA指南系统检索2000至2020年低级别与高级别胶质瘤术前接受新辅助化疗以改善切除程度的研究。个案报告与临床试验已报道新辅助化疗用于低级别胶质瘤以促进手术切除,而高级别胶质瘤相关证据较少。新辅助化疗有助于克服限制复杂胶质瘤(尤其低级别胶质瘤)切除程度的障碍。
要点
- 新辅助化疗可能缩小肿瘤体积或浸润,促进安全根治性切除。
- 低级别胶质瘤已有个案报告与临床试验支持该策略。
- 高级别胶质瘤应用新辅助化疗以改善切除程度的证据较少。
核心结论
- 新辅助化疗有助于克服限制复杂胶质瘤患者切除程度的障碍,尤其对低级别胶质瘤。
研究设计与样本
- 按PRISMA指南进行的系统综述,检索2000至2020年低级别与高级别胶质瘤术前接受新辅助化疗以改善切除程度的全文文章。
主要发现
- 已发表个案报告与临床试验,报道化疗作为新辅助治疗用于改善低级别胶质瘤的手术切除。
- 关于高级别胶质瘤手术中采用该策略的信息较为稀缺。
临床怎么用
- 对因体积或浸润而限制切除程度的复杂胶质瘤,可考虑术前新辅助化疗以促进安全根治性切除,低级别胶质瘤证据相对较多。
局限性
- 高级别胶质瘤相关证据稀缺。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Surgical resection plays a pivotal role in the management of glial tumors and a greater extent of resection (EOR) should be the goal in most surgeries to improve overall survival. Many factors may limit the EOR. A potential role for preoperative chemotherapy to decrease the volume and/or infiltration of gliomas, thereby facilitating a safe radical resection, has been recently suggested. This review aims to provide an overview of the current state of neoadjuvant therapy in the field of glioma surgery. METHODS: A systematic review was conducted according to PRISMA guidelines to identify articles of low- and high-grade gliomas that received neoadjuvant chemotherapy prior to surgery to improve the EOR from 2000 to 2020. Full-text articles that addressed this subject were included for evaluation. RESULTS: Case reports and clinical trials have been published for the use of chemotherapy as a neoadjuvant therapy to improve surgical resection in low-grade gliomas. More scarce information exists regarding this strategy for high-grade glioma surgery. CONCLUSIONS: Neoadjuvant chemotherapy has played a role in overcoming obstacles that limit the EOR in patients with complex gliomas, especially low-grade gliomas.
引用
- Jacobo JA, Mejia-Perez S, Moreno-Jimenez S, et al. The Role of Neoadjuvant Therapy to Improve the Extent of Resection in "Unresectable" Gliomas. World Neurosurg. 2020. PMID: 33137511. doi:10.1016/j.wneu.2020.10.109
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。